Transforming the Treatment of GI Diseases

Protecting Intestinal Barrier Health

Transforming the Treatment
of GI Diseases

Precision Delivery for Patient-Tailored Therapies that Protect Intestinal Integrity

Our mission is to identify, develop and commercialize novel therapeutics that target diseases resulting from a loss of gastrointestinal barrier integrity.

Science

Targeting Inflammatory Bowel Disease (IBD) Including Crohn’s Disease and Ulcerative Colitis

We are advancing a proprietary targeted prodrug platform to address the two most common forms of inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease.

Research Scientist

Science

Targeting Inflammatory Bowel Disease (IBD) Including Crohn’s Disease and Ulcerative

We are advancing a proprietary targeted prodrug platform to address the two most common forms of inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease.

Our Pipeline

DISCOVERY

Pre-Clinical

Phase 1

Phase 2

Phase 3

Ulcerative Colitis

Preclinical
Fibro Stenotic
Crohn’s Disease
Discovery

Investors and News

Important Events

[jsoncontentimporterpro nameoftemplate=”Events” param1=0]
[jsoncontentimporterpro nameoftemplate=”Events” param1=1]
[jsoncontentimporterpro nameoftemplate=”Events” param1=2]